A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

References

• Barlogie B, Shaughnessy J, Epstein J, . Plasma cell myeloma. Lichtman M, Beutler E, Kipps T, . Williams hematology. 7th. New York: McGraw-Hill; 2006. 1279–1304.
   Google Scholar
• Linker CA. Blood disorders. McPhee SJ, Papadakis MA, Tierney LM. Current medical diagnosis & treatment. 47th New York: McGraw-Hill; 2008. 422–472.
   Google Scholar
• Jemal A, Siegel R, Ward E, . Cancer Statistics. CA Cancer J Clin 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Kumar K, Blade J, Crowley J, . Outcome of patients with myeloma relapsing after IMID and bortezomib therapy: a multicenter study from the International Myeloma Foundation Working Group. Haematologica 2010;95(Suppl. 2): Abstract 0376.
   Google Scholar
• Goetz MP, Toft DO, Ames MM, . The HSP90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169–1176.
   PubMed Web of Science ®Google Scholar
• Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761–772.
   PubMed Web of Science ®Google Scholar
• Workman P, Burrows F, Neckers L, . Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 2007;1113:202–216.
   PubMed Web of Science ®Google Scholar
• Fumo G, Akin C, Metcalfe DD, . 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004;103:1078–1084.
   PubMed Web of Science ®Google Scholar
• Shimamura T, Lowell AM, Engelman JA, . Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005;65:6401–6408.
   PubMed Web of Science ®Google Scholar
• Ge J, Normant E, Porter JR, . Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of HSP90. J Med Chem 2006;49:4606–4615.
   PubMed Web of Science ®Google Scholar
• Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999;13:1211–1233.
   PubMed Web of Science ®Google Scholar
• Lee AH, Iwakoshi NN, Anderson KC, . Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003;100:9946–9951.
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, . Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907–4916.
   PubMed Web of Science ®Google Scholar
• Patterson J, Palombella VJ, Fritz C, . IPI-504, a novel and soluble HSP90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol 2008;61:923–932.
   PubMed Web of Science ®Google Scholar
• Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377–383.
   PubMed Web of Science ®Google Scholar
• Sydor JR, Normant E, Pien CS, . Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against HSP90. Proc Natl Acad Sci USA 2006;103:17408–17413.
   PubMed Web of Science ®Google Scholar
• Bladé J, Samson D, Reece D, . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcomittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, . A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609–2617.
   PubMed Web of Science ®Google Scholar
• Kim HR, Kang HS, Kim HD. Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life 1999;48:429–433.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toft D, Reid J, . Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078–1087.
   PubMed Web of Science ®Google Scholar
• Supko JG, Hickman RL, Grever MR, . Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305–315.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Trump DL, Eiseman JL, . Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385–3391.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, McCollum AK, Ames MM, . A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087–6093.
   PubMed Web of Science ®Google Scholar
• Grem JL, Morrison G, Guo XD, . Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885–1893.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Morgan JA, Chugh R, . Inhibition of heat shock protein (HSP90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. J Clin Oncol 2008;26(15 Suppl.): Abstract 10503.
   Web of Science ®Google Scholar
• Banerji U, Walton M, Raynaud F, . Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005;11:7023–7032.
   PubMed Web of Science ®Google Scholar
• Porter JR, Ge J, Lee J, . Ansamycin inhibitors of HSP90; nature's protoytpe for anti-chaperone therapy. Curr Top Med Chem 2009;9:1386–1418.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Chanan-Khan A, Lonial S, . Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: final results of a phase I/II study. J Clin Oncol 2009;27(15 Suppl.): Abstract 8503.
   Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ, . Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092–1100.
   PubMed Web of Science ®Google Scholar